Inhibitors of kinesin motor proteins--research and clinical progress

Curr Opin Drug Discov Devel. 2005 Jul;8(4):431-6.

Abstract

Molecules targeting mitosis, and specifically compounds targeting microtubule stability, are important in the treatment of cancer. Unfortunately, the mechanism of action of these agents can cause undesirable toxicities to healthy cells, inducing neurotoxicity and neutropenia in patients. In addition, many of these agents are subject to acquired resistance, usually through increased expression of membrane P-glycoprotein pumps. Due to the clinically proven utility of antimitotic therapeutics, the discovery of new agents with different mechanisms of action which may allow for the development of less toxic oncolytic treatments is highly desirable. This review describes key advances made over the last year toward the design and development of inhibitors of kinesin motor proteins, with particular emphasis placed on non-ATP-competitive, small-molecule inhibitors of kinesin spindle protein (Eg5).

Publication types

  • Review

MeSH terms

  • Animals
  • Antifungal Agents / pharmacology
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Cell Cycle Proteins / antagonists & inhibitors
  • Cell Division / drug effects
  • Cyclin-Dependent Kinase Inhibitor p27
  • Humans
  • Kinesin / antagonists & inhibitors*
  • Tumor Suppressor Proteins / antagonists & inhibitors

Substances

  • Antifungal Agents
  • Antineoplastic Agents
  • Cell Cycle Proteins
  • KIF11 protein, human
  • Tumor Suppressor Proteins
  • Cyclin-Dependent Kinase Inhibitor p27
  • Kinesin